Overview

Amifostine in Treating Young Patients With Newly Diagnosed De Novo Myelodysplastic Syndromes

Status:
Completed
Trial end date:
2009-10-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy, such as amifostine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. PURPOSE: This phase II trial is studying how well amifostine works in treating young patients with newly diagnosed de novo myelodysplastic syndromes.
Phase:
Phase 2
Details
Lead Sponsor:
Children's Oncology Group
Collaborator:
National Cancer Institute (NCI)
Treatments:
Amifostine